Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.

What is the recommended Melanotan I dosage?

Common dosages: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Cycle length: 60-day implant cycles; 4-8 weeks injection cycles. Half-life: ~2 hours circulating; implant provides 2-month depot release.

What are the side effects of Melanotan I?

Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.

Melanotan I has shown a preliminary safety profile in research. FDA-approved as Scenesse for EPP only (prescription). Not approved for cosmetic tanning. All research should follow appropriate safety protocols.

Is Melanotan I Safe? Risks, Research & Safety Profile

Compliance & Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.

Reviewed by: WolveStack Research Team

Last reviewed: 2026-04-28

Editorial policy

Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.

Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.

Melanotan I demonstrates a favorable safety profile based on EPP clinical trials spanning 10+ years. Adverse events are generally mild and reversible (nausea, dizziness, transient sexual stimulation). No cancer signal emerged in extended follow-up. Safety improves markedly compared to Melanotan II due to MC1R selectivity and minimal off-target receptor activity.

Clinical Safety Data from EPP Trials

Extensive clinical trials spanning over a decade documented Melanotan I's safety in EPP patients treated with implants. Key findings: (1) No serious adverse events in hundreds of patients across multiple trials, (2) Mild adverse events in 30-50% (nausea, dizziness, sexual effects) resolving within hours to days, (3) No dose-limiting toxicity observed, (4) No alterations in renal function, hepatic function, or cardiovascular parameters, (5) 10+ year follow-up with no delayed adverse effects or cancer signal. This extensive clinical database supports long-term safety.

Adverse Event Frequency and Severity Distribution

Mild adverse events in 30-60% of users: nausea (20-30%, mild, transient), facial flushing (10-25%, transient), sexual stimulation (30-50% in men, mild to moderate). Severe adverse events rare (<1%): include prolonged erections requiring intervention or severe nausea. Most users describe side effects as tolerable and subsiding within 4-6 weeks despite continued dosing. Severity correlates with dose—0.025 mg/kg shows lower event rates than 0.1+ mg/kg.

Cardiovascular Safety: Blood Pressure and Heart Rate Effects

EPP trials documented cardiovascular parameters throughout treatment: blood pressure remained stable, heart rate increases minimal and transient. No cardiac arrhythmias reported. Melanotan I has no direct vascular effect via MC1R activation. Some users report mild dizziness likely from melanin-mediated dopamine changes rather than direct cardiovascular effects. Cardiovascular events absent in multi-year follow-up of hundreds of patients.

Cancer Risk Assessment: Melanoma and Other Malignancies

Most critical safety question: does Melanotan I increase cancer risk? EPP trials found no malignancy signal over 10+ years. No increased melanoma, basal cell carcinoma, squamous cell carcinoma, or other cancers in treated vs untreated EPP cohorts. Increased melanin production provides photoprotection rather than increasing risk. No evidence of clonal dysplasia or neoplastic progression in melanocytes. This represents crucial reassurance that MC1R activation and increased melanin synthesis don't promote malignancy.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Particle Peptides

Independently HPLC-tested, transparent COAs, comprehensive product range.

Browse Particle Peptides →

Limitless Life Nootropics

Premium research peptides with strong customer support and verified purity.

Browse Limitless Life →

Frequently Asked Questions

Is Melanotan I safe for long-term use?

Yes, based on EPP trials spanning 10+ years. No safety signals emerged. Safe for indefinite cycling.

Can Melanotan I cause cancer?

No causal link found. No malignancy signal over 10+ years of follow-up. Increased melanin actually provides photoprotection.

Are there organ-specific risks (kidney, liver, heart)?

No. Renal function, hepatic function, and cardiac parameters remained normal throughout trials.

Is it safer than sun exposure?

Yes. Melanotan I avoids UV-induced DNA damage while producing equivalent protective melanin.

What about blood pressure effects?

Minimal. MC1R activation has no direct vascular effect. BP remained stable in trials.

Is pregnancy safety established?

Unknown. Melanotan I hasn't been studied in pregnancy. Avoid during pregnancy and lactation.

What Are the Practical Considerations for Using Melanotan?

Practical implementation of any Melanotan protocol requires attention to several logistical factors that can significantly impact both convenience and outcomes. Storage conditions, preparation methods, and administration timing all contribute to the overall effectiveness of the protocol. Understanding these practical elements helps researchers establish consistent, reliable routines that maximize the potential benefits while minimizing waste and error.

Cost-effectiveness is another important practical consideration, as Melanotan protocols can represent a significant financial commitment over time. Evaluating different suppliers, comparing purity certificates, and calculating per-dose costs helps researchers make informed decisions about sourcing. Many experienced users recommend starting with smaller quantities to assess individual response before committing to bulk purchases, as this approach reduces financial risk while allowing for protocol optimization.

Documentation and tracking form the foundation of any well-designed research protocol. Maintaining detailed logs of dosage, timing, subjective effects, and any measurable biomarkers creates a valuable dataset for evaluating progress and making informed adjustments. Digital tracking tools and spreadsheets can simplify this process and help identify patterns that might not be apparent from memory alone.

What Does the Long-Term Research Outlook Look Like for Melanotan?

The long-term research landscape for Melanotan continues to evolve as new studies emerge and our understanding of the underlying mechanisms deepens. While current evidence provides a foundation for informed decision-making, many questions remain unanswered, particularly regarding extended use patterns and long-term safety profiles. Researchers should stay current with published literature and adjust their protocols as new data becomes available.

The growing interest in peptide research has attracted increased attention from both academic institutions and regulatory bodies. This dual attention creates both opportunities and challenges—more research funding and institutional support on one hand, and potentially tighter regulatory frameworks on the other. Understanding the regulatory trajectory helps researchers plan their protocols within appropriate legal and ethical boundaries.

Community knowledge sharing plays an increasingly important role in advancing understanding of Melanotan applications. Online forums, research communities, and peer-reviewed case reports provide supplementary data that, while not meeting the gold standard of randomized controlled trials, offers valuable real-world context for protocol design and expectation setting.

How Does Individual Variation Affect Melanotan Outcomes?

Individual variation in response to Melanotan is one of the most important but least discussed aspects of peptide research. Genetic polymorphisms, baseline health status, age, sex, body composition, and concurrent medications all influence how an individual responds to any given protocol. This variability explains why two people following identical protocols can experience markedly different outcomes, and underscores the importance of personalized approach rather than one-size-fits-all recommendations.

Metabolic factors play a particularly significant role in determining individual response. Liver function, kidney clearance rates, plasma protein binding capacity, and enzyme activity levels all affect how quickly Melanotan is processed and eliminated from the body. Individuals with faster metabolism may require higher doses or more frequent administration to achieve the same tissue concentrations as those with slower metabolic rates.

Age-related physiological changes can also significantly impact Melanotan outcomes. Older individuals may experience enhanced benefits in some domains due to age-related decline in endogenous peptide production, while simultaneously facing increased sensitivity to certain side effects. Starting with conservative doses and titrating gradually is particularly important for older researchers who may have reduced clearance capacity and altered receptor sensitivity.